&nbsp;

Nov 2024

Drug

bleomycin

Quick Link(s):

Nov 2024

Drug

denosumab

Other Name(s): Xgeva®; Wyost™

Quick Link(s):

Oct 2024

Drug

bendamustine

Other Name(s): Treanda®

Quick Link(s):

Nov 2024

Drug

brentuximab vedotin

Other Name(s): Adcetris®

Quick Link(s):

Jun 2025

Drug

daBRAFenib

Other Name(s): Tafinlar®

Quick Link(s):

Jun 2025

Drug

bosutinib

Other Name(s): Bosulif®

Quick Link(s):

Nov 2024

Drug

daratumumab

Other Name(s): Darzalex®

Quick Link(s):

Jan 2023

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DCRB

Cancer Type:

Sarcoma,

Soft Tissue,

Skin,

Melanoma

Intent: Palliative

Drugs Used:

dacarbazine

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DCTN

Cancer Type:

Gynecologic,

Gestational Trophoblastic Disease

Intent: Curative

Drugs Used:

DACTINomycin

Quick Link(s):

Regimen Monograph

Jun 2020

Regimen

DEXA(PO)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

dexamethasone